- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Berlex recalls tainted lot of Ultravist CT contrast media
Berlex initiated a nationwide recall July 20 to retrieve a single lot of Ultravist after particulate matter associated with crystallization was found in vials of the intravenous x-ray and CT contrast medium.
Berlex initiated a nationwide recall July 20 to retrieve a single lot of Ultravist after particulate matter associated with crystallization was found in vials of the intravenous x-ray and CT contrast medium.
The recall is limited to lot No. 41500A of Ultravist Injection 370 mgI/mL, 125 mL, (iopromide injection), NDC 50419-346-12. The expiration date is January 2007.
Particulate matter found in the vial poses serious safety problems, including vascular thrombosis, thromboembolism, and injury to the heart, kidney, and brain, the company said in a release.
Berlex voluntarily instigated the recall after two customers complained about vials exhibiting crystallization. An investigation was begun to determine if other lots of Ultravist were affected, the company said
Berlex customers were asked to inspect their inventories for Ultravist from the affected lot. If found, the product should be quarantined immediately to prohibit its use in medical imaging.
Berlex should be contacted at 866/237-5395 to orchestrate the return of contaminated vials. Adverse reactions or quality problems with Ultravist should be reported to the FDA's Medwatch Adverse Event Reporting program or by phone at 800/332-1088.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
